The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
Open accessAbstract
Minimal residual disease (MRD) at the end of remission-induction therapy predicts relapse in acute lymphoblastic leukemia (ALL). We examined the clinical significance of levels below the usual threshold value for MRD positivity (0.01%) in 455 children with B-lineage ALL, using polymerase chain reaction amplification of antigen-receptor genes capable of detecting at least 1 leukemic cell per 100 000 normal mononucleated cells (0.001%). Of the 455 clinical samples studied on day 46 of therapy, 139 (30.5%) had MRD 0.001% or more with 63 of these (45.3%) showing levels of 0.001% to less than 0.01%, whereas 316 (69.5%) had levels that were either less than 0.001% or undetectable. MRD measurements of 0.001% to less than 0.01% were not significantly related to presenting characteristics but were associated with a poorer leukemia cell clearance on day 19 of remission induction therapy. Patients with this low level of MRD had a 12.7% (± 5.1%; SE) cumulative risk of relapse at 5 years, compared with 5.0% (± 1.5%) for those with lower or undetectable MRD (P < .047). Thus, low levels of MRD (0.001%-< 0.01%) at the end of remission induction therapy have prognostic significance in childhood ALL, suggesting that patients with this finding should be monitored closely for adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Self-citation
Cited by
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Self-citationBerry, D. A., Zhou, S., Higley, H., Mukundan, L., Fu, S., Reaman, G. H., Wood, B. L., Kelloff, G. J., Jessup, J. M., & Radich, J. P. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0580 · Cited by 599
Theunissen, P., Mejstrikova, E., Sedek, L., van der Sluijs-Gelling, A. J., Gaipa, G., Bartels, M., Sobral da Costa, E., Kotrová, M., Novakova, M., Sonneveld, E., et al. (2017) · Blood · doi:10.1182/blood-2016-07-726307 · Cited by 435
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Faham, M., Zheng, J., Moorhead, M., Carlton, V. E. H., Stow, P., Coustan-Smith, E., Pui, C.-H., & Campana, D. (2012) · Blood · doi:10.1182/blood-2012-07-444042 · Cited by 423
Self-citationA 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.06.007 · Cited by 368
Self-citation
Metadata
- Authors
- Stow, P., Key, L., Chen, X., Pan, Q., Neale, G. A., Coustan-Smith, E., Mullighan, C. G., Zhou, Y., Pui, C.-H., & Campana, D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-06-10
- Volume
- 115
- Issue
- 23
- Pages
- 4657-4663
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2034592954
- Cited by
- 159
- References
- 1
- FWCI
- 15.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1182/blood-2009-11-253435
- The paper
- Stow, P., Key, L., Chen, X., Pan, Q., Neale, G. A., Coustan-Smith, E., Mullighan, C. G., Zhou, Y., Pui, C.-H., & Campana, D. (2010). Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood. https://doi.org/10.1182/blood-2009-11-253435
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.